Follistatin-like 1 and its paralogs in heart development and
cardiovascular disease

J 2022

Follistatin-like 1 and its paralogs in heart development and cardiovascular disease

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ, Julie DOBROVOLNÁ et. al.

Základní údaje

Originální název

Follistatin-like 1 and its paralogs in heart development and cardiovascular disease

Autoři

HOŘÁK, Martin (203 Česká republika, domácí), DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN (246 Finsko, domácí), David BEDNÁŘ (203 Česká republika, domácí) a Julie DOBROVOLNÁ (203 Česká republika, garant, domácí)

Vydání

Heart Failure Reviews, New York, Springer US, 2022, 1382-4147

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.600

Kód RIV

RIV/00216224:14310/22:00127632

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1007/s10741-022-10262-6

UT WoS

000828956200001

Klíčová slova anglicky

FSTL1; FSTL4; FSTL5; Heart failure; Inflammation

Štítky

14110518, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 8. 2023 09:32, Mgr. Marie Šípková, DiS.

Anotace

V originále

Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.

Návaznosti

EF15_003/0000469, projekt VaV

Název: Cetocoen Plus

EF17_043/0009632, projekt VaV

Název: CETOCOEN Excellence

LM2018121, projekt VaV

Název: Výzkumná infrastruktura RECETOX (Akronym: RECETOX RI)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, RECETOX RI

NU22-02-00418, projekt VaV

Název: Klinické a proteomické biomarkery predikující reverzní remodelaci levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií

Investor: Ministerstvo zdravotnictví ČR, Klinické a proteomické biomarkery predikujcí reverzní remodelování levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií, Podprogram 1 - standardní

857560, interní kód MU
(Kód CEP: EF17_043/0009632)

Název: CETOCOEN Excellence (Akronym: CETOCOEN Excellence)

Investor: Evropská unie, CETOCOEN Excellence, Spreading excellence and widening participation

Citovat

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ a Julie DOBROVOLNÁ. Follistatin-like 1 and its paralogs in heart development and cardiovascular disease. Heart Failure Reviews. New York: Springer US, 2022, roč. 27, č. 6, s. 2251-2265. ISSN 1382-4147. Dostupné z: https://dx.doi.org/10.1007/s10741-022-10262-6.

@article{2243097,
   author = {Hořák, Martin and Fairweather, DeLisa and Kokkonen, Piia Pauliina and Bednář, David and Dobrovolná, Julie},
   article_location = {New York},
   article_number = {6},
   doi = {http://dx.doi.org/10.1007/s10741-022-10262-6},
   keywords = {FSTL1; FSTL4; FSTL5; Heart failure; Inflammation},
   language = {eng},
   issn = {1382-4147},
   journal = {Heart Failure Reviews},
   note = {Korespondenční autor nereagoval na žádost o doplnění podílu. Podíl doplněn rovnocenně podle počtu participujících HS (dle rozhodnutí vedení PřF).},
   title = {Follistatin-like 1 and its paralogs in heart development and cardiovascular disease},
   url = {https://link.springer.com/article/10.1007/s10741-022-10262-6},
   volume = {27},
   year = {2022}
}

TY  - JOUR
ID  - 2243097
AU  - Hořák, Martin - Fairweather, DeLisa - Kokkonen, Piia Pauliina - Bednář, David - Dobrovolná, Julie
PY  - 2022
TI  - Follistatin-like 1 and its paralogs in heart development and cardiovascular disease
JF  - Heart Failure Reviews
VL  - 27
IS  - 6
SP  - 2251-2265
EP  - 2251-2265
PB  - Springer US
SN  - 13824147
N1  - Korespondenční autor nereagoval na žádost o doplnění podílu. Podíl doplněn rovnocenně podle počtu participujících HS (dle rozhodnutí vedení PřF).
KW  - FSTL1
KW  - FSTL4
KW  - FSTL5
KW  - Heart failure
KW  - Inflammation
UR  - https://link.springer.com/article/10.1007/s10741-022-10262-6
N2  - Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.
ER  -

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ a Julie DOBROVOLNÁ. Follistatin-like 1 and its paralogs in heart development and cardiovascular disease. \textit{Heart Failure Reviews}. New York: Springer US, 2022, roč.~27, č.~6, s.~2251-2265. ISSN~1382-4147. Dostupné z: https://dx.doi.org/10.1007/s10741-022-10262-6.

Podrobný výpis o publikaci